‘Global Interventional Cardiology Market Worth $13,920m In 2021’ Says Visiongain Report

28 August 2018
Pharma

Visiongain’s new report Global Interventional Cardiology Market 2017-2027: Percutaneous Coronary Intervention (PCI), Transcatheter Aortic Valve Implantation (TAVI), Transcatheter Mitral Valve Implantation (TMVR) indicates that the global interventional cardiology market will see $13,920m in spending in 2021.

The global interventional cardiology market is expected to grow at a CAGR of 11.1% in the first half of the forecast period and CAGR of 16.9% in the second half of the forecast period. The market is expected to grow at a CAGR of 15.0% from 2017 to 2027. The market is estimated at $13,920m in 2021 and $35,537m in 2027.

The lead analyst of the report said: “The Interventional Cardiology market is anticipated to witness a robust growth during the years of forecast owing to the growing awareness of existing technologies, launch of new innovative products and rapid adoption of these emerging technologies in developed countries such as US and Europe. Moreover, we anticipate more companies entering this market during the forecast period while; the existing players would try to fortify their global position through geographical expansion by setting up their operations in emerging economies such as China, India, Brazil, Russia and Middle East.
The growing prevalence of coronary heart diseases, aortic stenosis and mitral valve stenosis have triggered the demand for more innovative and less invasive. Hence, demand for interventional cardiac procedures is expected to drive the growth of interventional cardiology devices market. The TAVR and TMVR devices are expected to have high growth rate in the coming years. Visiongain also expects the bioresorbable stents market to witness a robust growth during the forecast period. However; premium pricing of these products may hinder the growth of the market especially in countries with weak social insurance structure.”
The 225-page report contains 111 charts that add visual analysis in order to explain the developing trends within the Global Interventional Cardiology Market. Visiongain provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the leading segments of this market: Percutaneous Coronary Intervention (PCI), Transcatheter Aortic Valve Implantation (TAVI), Transcatheter Mitral Valve Implantation (TMVR). The PCI submarket is further segmented into Drug-eluting Stents (DES), Bare Metal Stents, and Bioresorbable Stents

The 225-page report offers market forecasts for the US, Germany, France, Italy, Spain, the UK, Japan, Australia, Singapore, China, India and the Rest of the World (RoW). Each country is further segmented into PCI, TAVI and TMVR.

In addition, the report contains a dedicated leading companies’ chapter covering the leading companies in this field.

The report Global Interventional Cardiology Market 2017-2027: Percutaneous Coronary Intervention (PCI), Transcatheter Aortic Valve Implantation (TAVI), Transcatheter Mitral Valve Implantation (TMVR) report will be of value to anyone who wants to better understand the interventional cardiology market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the interventional cardiology industry.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Food for Special Medical Purpose (FSMP) Market Report 2020-2030

The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.

12 April 2021

Read

Visiongain Publishes Cell-Based Assays Market Report to 2030

Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.

09 April 2021

Read

Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031

The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

06 April 2021

Read

Visiongain Publishes Artificial Intelligence (AI) in Drug Discovery Market Report 2021-2031

Factors such as increasing data volumes for analysis, quick turnaround time for the discovery and development new drug, computing power, AI also helps in targeted manufacturing and others drive the market growth.

01 April 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever